You should know these things about COVID-19 specific drug 3CL protease inhibitor

If you pay attention to specific anti COVID-19 drugs, you will definitely know the term “3CL protease inhibitor”, which is one of the hot targets of COVID-19 drug development. Xiansheng Pharmaceutical’s Xiannuoxin (Xiannuoxue tablets/Litonavir tablets), which has been approved for market launch, and Guangsheng Zhonglintai Zhongdingtai Zhongdingtai, which is currently undergoing phase III clinical trials ® (Taiatewei GST-HG171 tablets combined with ritonavir tablets) and others belong to 3CL protease inhibitors.
3CL protease is an indispensable proteolytic enzyme in the replication process of COVID-19. It can promote the decomposition of antioxidant protein GPx1, reduce its nearby antioxidant activity, promote its own formation of aggregates and improve its protease activity, and finally achieve the improvement of virus replication and transcription level.
3CL protease inhibitor, “cutting” the chain of self replication of COVID-19
The 3CL protease target is relatively conserved in coronaviruses and is the main protease necessary for gene cleavage in the offspring of coronaviruses. Inhibiting the activity of 3CL protease can prevent protein precursors from being cleaved and participating in assembly to form mature viral bodies, interfering with the virus replication process and thus blocking the virus’s self replication. Due to the absence of proteases homologous to 3CL protease in the human body, 3CL protease inhibitors have a higher level of safety.